Latest Biotech News

Incyte is buying Vega Therapeutics’ subsidiary Star Therapeutics’ Vega unit in a $1.25 billion upfront package, targeting a late-stage von Willebrand disease (VWD) candidate in Phase III...

Roche agreed to pay Nurix Therapeutics $700 million upfront to co-develop and co-commercialize bexobrutideg, an oral BTK degrader that Roche believes could take share in B-cell malignancies. The...

Two major transactions reinforced a broader 2026 pattern of Big Pharma paying for late-stage or near-late-stage oncology and immunotherapy platforms. In one deal stream, Incyte’s Vega acquisition...

Tango reported early clinical results showing its PRMT5 inhibitor vopimetostat may add to daraxonrasib activity in metastatic pancreatic ductal adenocarcinoma, lifting the response profile in a...

Treeline Biosciences announced plans to enter public markets through an all-stock reverse merger with Standard BioTools, combining precision oncology capabilities with Treeline’s oncology...

City Therapeutics raised $99.5 million in a Series B financing to expand development of three RNAi candidates and to broaden beyond initial liver-focused targets. The startup—built by former...

Amphista Therapeutics received FDA IND clearance for AMX-883, an orally bioavailable degrader of BRD9 intended for acute myeloid leukemia (AML). The company expects to start a Phase I trial in...

Google DeepMind and the Wellcome Sanger Institute launched an AI genomics consortium to build large genomic datasets intended to train predictive biological machine learning models. Google.org...

VolitionRx priced a public offering of common stock and warrants that could raise gross proceeds of $4.6 million, with additional proceeds possible if warrants are fully exercised. The company...

FDA approved sonrotoclax (Beqalzi), a Bcl-2 inhibitor, in May 2026 for mantle cell lymphoma patients who have tried at least two prior therapies, positioning the drug as the second Bcl-2 inhibitor...

Incyte moved into a late-stage blood disorder bet by agreeing to buy Star Therapeutics’ Vega subsidiary for $1.25 billion upfront, plus up to $750 million in sales milestones, to secure phase...

Roche committed $700 million upfront to partner with Nurix on bexobrutideg, an oral BTK degrader for B-cell malignancies, with milestones that could increase the total to $2.3 billion. The...

Tango Therapeutics and Revolution Medicines reported additional early-stage evidence for a pancreatic cancer combination built around vopimetostat, a PRMT5 inhibitor, paired with Revolution’s...

Interim expansion data from Tango’s PRMT5 inhibitor vopimetostat in combination with Revolution’s RAS(ON) inhibitors showed durable responses in an early clinical study in metastatic PDAC, with...

Texas A&M Health Institute researchers unveiled CODS, an AI-designed, caffeine-activated protein dissociation system intended to give engineered cells a controllable “pause” mechanism. Published...

City Therapeutics, an RNAi startup founded by former Alnylam executives, raised $99.5 million to accelerate clinical development of its first three RNAi candidates and expand beyond liver-focused...

Genomtec secured €2.6 million equity financing to support commercialization of its molecular diagnostics platforms, including a portable microfluidic system (Genomtec ID) and OncoSNAAT liquid...

Treeline Biosciences announced it will go public via a reverse merger with Standard BioTools, in an all-stock transaction valued around Standard BioTools’ net cash position plus additional value...

Nature Biotechnology published new work on sub-zero technologies designed to reduce ice damage in organs, with the goal of extending donor-graft shelf life and giving transplant centers more time...

Incyte has agreed to acquire Vega Therapeutics in a deal valued at $1.25 billion upfront, positioning Vega’s Phase III von Willebrand disease asset VGA039 as a potential next growth driver as...